Crataegus Monogyna Flower

Dosage for Crataegus Monogyna Flower allergenic extract is highly individualized and must be determined by a physician based on the patient's sensitivity level. There is no 'standard' dose, as the extract is non-standardized and potency is often expressed in Protein Nitrogen Units (PNU) or Weight/Volume (W/V) ratios.

Diagnostic Testing

• Prick/Scratch Test: Usually performed using a 1:10 or 1:20 W/V concentration. A single drop is applied to the skin, and the skin is pricked through the drop.
• Intradermal Test: If prick tests are negative, a 1:100 or 1:1000 W/V dilution may be injected (0.02 mL to 0.05 mL) to create a small bleb.

Immunotherapy (SCIT)

• Build-up Phase: Starts with a very low dose (e.g., 0.1 mL of a 1:100,000 W/V dilution) administered once or twice weekly. The dose is increased by 25% to 50% at each visit until the maintenance dose is reached.
• Maintenance Phase: Once the maximum tolerated dose is reached (the 'maintenance dose'), injections are typically given every 2 to 4 weeks. A common maintenance dose range is 0.5 mL of a 1:100 or 1:20 W/V solution.

Crataegus Monogyna Flower extract is used in pediatric patients, but dosing must be approached with extreme caution. Children are at the same risk for systemic reactions as adults. Dosing schedules generally follow the adult protocol but may involve smaller volume increments during the build-up phase. There is no specific age cutoff, though immunotherapy is rarely started in children under the age of 5 due to the difficulty of monitoring for early signs of anaphylaxis.

Renal Impairment

No specific dosage adjustments are provided for renal impairment, as the extract is not significantly cleared by the kidneys in its active form. However, patients with severe renal disease may be at higher risk if emergency medications (like epinephrine) need to be administered.

Hepatic Impairment

No dosage adjustments are required for hepatic impairment.

Elderly Patients

Elderly patients (over 65) should be evaluated for cardiovascular stability before starting immunotherapy. If an elderly patient is taking beta-blockers for hypertension, immunotherapy is generally discouraged due to the risk of refractory anaphylaxis.

• Administration: This medication is ONLY administered by a healthcare professional in a clinical setting. It is given via subcutaneous injection (usually in the posterior aspect of the upper arm).
• Observation: Patients MUST remain in the medical office for at least 30 minutes following every injection to monitor for systemic allergic reactions.
• Storage: Extracts should be stored at 2°C to 8°C (36°F to 46°F). Freezing will denature the proteins and render the extract ineffective.

If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated, depending on how much time has passed. If more than 4 weeks have passed since the last dose, the physician will typically restart the titration from a lower concentration to ensure safety.

An overdose of allergenic extract (either by volume or concentration) can lead to immediate, life-threatening anaphylaxis. Symptoms include generalized hives, swelling of the throat, wheezing, hypotension (low blood pressure), and loss of consciousness. Emergency treatment with epinephrine, antihistamines, and corticosteroids is required immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Never attempt to self-administer allergenic extracts.

Most patients receiving Crataegus Monogyna Flower extract will experience local reactions at the site of injection. These are generally not dangerous but can be uncomfortable.

• Local Erythema (Redness): Redness around the injection site that usually appears within minutes and fades within a few hours.
• Local Pruritus (Itching): Intense itching at the injection site.
• Swelling: A small 'knot' or wheal at the injection site. If the swelling is larger than a half-dollar (approx. 3 cm), it is considered a 'large local reaction' and may require a dose adjustment for the next visit.

• Fatigue: Many patients report feeling unusually tired for several hours after an allergy injection.
• Headache: Mild to moderate tension-type headaches.
• Delayed Local Reaction: Swelling and redness that appear 6 to 24 hours after the injection. These are often managed with cold compresses and oral antihistamines.

• Generalized Urticaria (Hives): Hives appearing on parts of the body other than the injection site.
• Angioedema: Swelling of the lips, eyelids, or extremities.
• Rhinitis: Sneezing and nasal congestion triggered by the injection itself.

> Warning: Stop taking Crataegus Monogyna Flower and call your doctor immediately if you experience any of these symptoms of anaphylaxis.

• Respiratory Distress: Wheezing, chest tightness, or difficulty breathing. This indicates bronchospasm.
• Laryngeal Edema: A feeling of a 'lump in the throat,' hoarseness, or difficulty swallowing.
• Hypotension: Dizziness, fainting, or a rapid, weak pulse, indicating a drop in blood pressure.
• Gastrointestinal Distress: Severe abdominal cramping, vomiting, or diarrhea occurring shortly after an injection.
• Cyanosis: Bluish tint to the lips or fingernails due to lack of oxygen.

There are no known long-term 'toxic' effects of Crataegus Monogyna Flower extract on organs like the liver or kidneys. The primary long-term risk is the cumulative risk of experiencing a systemic reaction over the course of several years of therapy. Some patients may develop 'serum sickness-like' symptoms (joint pain, fever) if they are receiving extremely high doses of foreign proteins, though this is exceptionally rare with modern extracts.

WARNING: RISK OF SEVERE ALLERGIC REACTION

Crataegus Monogyna Flower allergenic extract can cause severe, life-threatening systemic reactions, including anaphylaxis. Fatalities have occurred.

• This product must only be administered in a setting where emergency equipment and personnel trained in treating anaphylaxis are immediately available.
• Patients must be observed for at least 30 minutes following administration.
• Patients with unstable asthma are at a significantly higher risk for fatal reactions.
• Patients taking beta-blockers may be resistant to the effects of epinephrine used to treat a reaction.

Report any unusual symptoms to your healthcare provider immediately. Always carry your prescribed epinephrine auto-injector if you are undergoing immunotherapy.

Crataegus Monogyna Flower extract is a potent biological agent. It is not a 'supplement' or 'herbal remedy' when used in this clinical context; it is a regulated allergen. Safety depends entirely on proper administration and patient monitoring.

Allergenic Extract Warning: Crataegus Monogyna Flower extract carries a boxed warning regarding the risk of anaphylaxis. It should not be administered to patients with severe, unstable, or steroid-dependent asthma. The risk of a fatal systemic reaction is increased in patients who have recently experienced an asthma exacerbation.

• Anaphylaxis Risk: Every injection carries a non-zero risk of anaphylaxis. Patients must be educated on the early signs (itchy palms, throat clearing, 'sense of impending doom').
• Asthma Status: If a patient is wheezing or has a peak flow significantly below their personal best on the day of the injection, the dose must be withheld.
• Acute Illness: Injections should be deferred if the patient has a fever or an active viral infection, as the immune system is already 'primed' and more likely to overreact to the allergen.
• Exercise: Patients should avoid vigorous exercise for 2 hours before and 2 hours after an injection, as increased circulation can speed up the absorption of the allergen and trigger a reaction.

• Initial Assessment: A thorough history and physical exam, including pulmonary function testing (Spirometry), must be performed before starting therapy.
• Ongoing Monitoring: Before every injection, the clinician must check for late-phase reactions from the previous dose and assess current asthma/allergy symptoms.
• Observation Period: A mandatory 30-minute post-injection wait time is the standard of care.

While the extract itself does not cause sedation, a systemic reaction or the administration of antihistamines/epinephrine to treat a reaction can significantly impair the ability to drive or operate machinery. Patients should be cautious until they know how they respond to the treatment.

Alcohol consumption should be avoided on the day of the injection. Alcohol can cause vasodilation, which may increase the rate of allergen absorption and potentially lower the threshold for a systemic reaction.

Immunotherapy is typically discontinued after 3 to 5 years of successful treatment. If a patient experiences a severe systemic reaction, the physician may decide to discontinue therapy permanently if the risks outweigh the benefits. There is no 'withdrawal' syndrome, but allergy symptoms may return if therapy is stopped prematurely.

> Important: Discuss all your medical conditions with your healthcare provider before starting Crataegus Monogyna Flower.

• Beta-Blockers (Non-selective and Selective): Drugs like Propranolol, Atenolol, or Metoprolol are generally contraindicated during immunotherapy. If a patient on a beta-blocker experiences anaphylaxis, the beta-blocker prevents epinephrine from working effectively on the heart and lungs, making the reaction potentially fatal.
• MAO Inhibitors (MAOIs): Medications like Phenelzine or Tranylcypromine can potentiate the effects of pressor amines used to treat anaphylaxis, leading to hypertensive crisis.

• ACE Inhibitors: Some studies suggest that patients taking ACE inhibitors (e.g., Lisinopril) may be at higher risk for more severe systemic reactions during immunotherapy.
• Tricyclic Antidepressants (TCAs): Like MAOIs, TCAs (e.g., Amitriptyline) can interfere with the body's response to emergency medications used during a reaction.

• Antihistamines: While not dangerous, H1-antagonists (e.g., Cetirizine, Loratadine) will suppress the skin's response to Crataegus Monogyna Flower during diagnostic testing. These must be discontinued 3 to 7 days before skin testing to avoid false-negative results.
• H2 Blockers: Medications like Famotidine can also slightly blunt the skin test response and should be discontinued 48 hours prior to testing.
• Systemic Corticosteroids: Long-term use of oral prednisone may suppress the immune response to immunotherapy or mask the early signs of a reaction.

• Cross-Reactive Foods: Patients allergic to Crataegus (Hawthorn) may experience Oral Allergy Syndrome (OAS) when eating related fruits from the Rosaceae family, such as apples, pears, cherries, or peaches. Consuming these foods immediately before or after an injection may increase the risk of a reaction.

• Hawthorn Supplements: Patients taking oral Hawthorn berry or flower supplements for heart health should inform their doctor. While the oral supplement is different from the injectable extract, the combined exposure to Crataegus proteins could theoretically lower the allergic threshold.

• Skin Prick Tests: As mentioned, antihistamines and certain antidepressants will interfere with the results of skin tests.
• Specific IgE (ImmunoCAP): Crataegus Monogyna Flower extract treatment will eventually cause an increase in IgG4 levels and a potential decrease in specific IgE levels over several years, which is the intended therapeutic effect.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe, Unstable Asthma: Patients with an FEV1 (Forced Expiratory Volume) consistently below 70% of predicted are at an unacceptable risk for fatal bronchospasm during immunotherapy.
• Recent Myocardial Infarction (Heart Attack): The cardiovascular stress of a potential anaphylactic reaction is too great for patients with unstable cardiac disease.
• History of Severe Anaphylaxis to Immunotherapy: If a patient has previously experienced a near-fatal reaction to allergenic extracts, the treatment is generally permanently contraindicated.
• Inability to Communicate: Patients who cannot describe early symptoms of a reaction (e.g., very young children or patients with severe cognitive impairment) should not receive this treatment.

• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may experience an exacerbation of their condition if the immune system is stimulated with allergenic extracts.
• Malignancy: Patients undergoing active chemotherapy or radiation should delay immunotherapy until their condition is stable.
• Beta-Blocker Therapy: While often considered an absolute contraindication, some specialists may perform a risk-benefit analysis if the patient's allergy is life-threatening and no other heart medications are suitable.

Patients with known allergies to other members of the Rosaceae family (including Rose, Apple, Pear, Cherry, and Plum) may exhibit cross-sensitivity to Crataegus Monogyna Flower. This means they are more likely to test positive for this allergen and may react more strongly to the extract.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Crataegus Monogyna Flower.

FDA Pregnancy Category C. There are no adequate and well-controlled studies of Crataegus Monogyna Flower extract in pregnant women.

• Risk of Anaphylaxis: The primary concern during pregnancy is not the extract itself, but the risk of a systemic reaction. Anaphylaxis in the mother can lead to maternal hypotension, which causes fetal hypoxia (lack of oxygen to the baby), potentially leading to miscarriage or neurological damage.
• Clinical Practice: Immunotherapy is typically NOT started during pregnancy. However, if a woman is already on a stable maintenance dose and is tolerating it well, the physician may choose to continue the therapy at the same or a slightly reduced dose.

It is not known whether the allergenic proteins in Crataegus Monogyna Flower extract are excreted in human milk. However, because these are large proteins that are digested in the infant's gut, the risk to a nursing infant is considered negligible. The primary concern remains the mother's safety and the management of any potential reactions.

Immunotherapy with Crataegus Monogyna Flower is effective in children for reducing the progression from allergic rhinitis to asthma (the 'allergic march').

• Age Limits: It is generally avoided in children under 5 years of age.
• Growth Effects: There is no evidence that allergenic extracts affect growth or development in children.

Patients over 65 are at higher risk for complications from immunotherapy due to the prevalence of cardiovascular disease. The ability to tolerate the physiological stress of anaphylaxis decreases with age. Furthermore, polypharmacy (taking multiple medications) increases the likelihood of drug interactions with emergency medications.

No specific studies have been conducted in patients with renal impairment. Because the extract is a biological protein mixture, it does not require renal-based dose adjustments. However, clinicians should be cautious in patients with end-stage renal disease who may have compromised cardiovascular compensatory mechanisms.

No dose adjustment is required for patients with liver disease. The metabolism of allergenic proteins occurs via general proteolytic pathways throughout the body, not specifically in the liver.

> Important: Special populations require individualized medical assessment.

Crataegus Monogyna Flower extract acts as an immunomodulator. In a sensitized individual, exposure to the allergen normally results in the binding of the allergen to IgE antibodies on mast cells and basophils. This causes the release of histamine, leukotrienes, and cytokines (Type I Hypersensitivity).

When administered as immunotherapy, the extract induces several changes:

1. 1T-Cell Desensitization: It promotes the development of T-regulatory (Treg) cells that produce IL-10 and TGF-beta, which suppress allergic inflammation.
2. 2Antibody Class Switching: It shifts B-cell production from IgE to IgG4. IgG4 acts as a 'blocking antibody,' intercepting the allergen before it can reach the IgE on mast cells.
3. 3Reduced Effector Cell Recruitment: Over time, there is a decrease in the number of mast cells and eosinophils in the shock organs (the nose and lungs).

• Onset of Action: For diagnostic skin testing, the effect is seen in 15-20 minutes. For immunotherapy, clinical improvement typically takes 6 to 12 months of consistent treatment.
• Duration of Effect: The 'tolerance' induced by a full course (3-5 years) of immunotherapy can last for many years, sometimes permanently, after treatment stops.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Intradermal) |

| Protein Binding | N/A (Biological proteins) |

| Half-life | Variable (Days for proteins; Years for immune effect) |

| Tmax | 15-30 minutes (Local reaction) |

| Metabolism | Proteolysis by various tissues |

| Excretion | Renal (as peptide fragments) |

• Source: Pollen of Crataegus monogyna (English Hawthorn).
• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides. The specific major allergens in Crataegus have not been as extensively characterized as those in grasses or ragweed, which is why it remains a 'non-standardized' extract.
• Solubility: Soluble in aqueous buffers and glycerinated solutions.

Crataegus Monogyna Flower is classified as a Non-Standardized Plant Allergenic Extract. It is grouped with other deciduous tree and shrub pollens used in clinical allergy practice.